Introduction
Oral mucositis is a common complication of cancer therapy. Mucositis results from damage to the mucosal epithelium after delivery of chemotherapy or radiation treatments designed to treat the cancer. A number of treatment factors have been shown to influence the incidence and severity of mucositis, including site and fractionation schedule of radiation, chemotherapy type and dosage.
1,2 High-dose chemotherapy can cause severe oral mucositis and is often the side effect that patients find the most difficult to endure. 3 Single-agent high-dose melphalan followed by autologous stem cell support has emerged as an important treatment option for patients with multiple myeloma. 4, 5 Melphalan at doses 4140 mg/m 2 results in severe mucositis in the majority of patients. This complication accounts for increased morbidity and may result in infections, the need for intravenous feeding, narcotics and extended hospitalization. Prolonged use of narcotics can lead to ileus, gastrointestinal toxicity and may result in increased use of total parenteral nutrition (TPN). 6 The only approved agent for prevention of mucositis associated with high-dose therapy is palifermin, but several studies have shown that low-energy lasers or amifostine can reduce the incidence and severity of mucositis. 7, 8 Additionally, there have been several reports of reduced oral mucositis in patients who kept ice chips in their mouth during infusional chemotherapy. 9, 10 The scientific rationale for this approach is that cryotherapy leads to vasoconstriction and decreased blood flow to the oral cavity, which reduces the exposure of the buccal mucosa to chemotherapy. There are no randomized trials that report on the use of cryotherapy in patients receiving high-dose melphalan, and the reported single-arm studies were conducted in association with other drugs or total body irradiation. 11, 12 The preliminary data supporting this study question came from observations of four patients with multiple myeloma conditioned with melphalan 200 mg/m 2 in January 2003, who received cryotherapy during and after the melphalan infusion. These four patients were compared to 20 patients diagnosed with multiple myeloma who received melphalan 140-200 mg/m 2 followed by transplantation with autologous peripheral blood stem cells in 2002 who did not receive cryotherapy. The incidence of grade 3-4 mucositis was 0% in the ice-chip group and 70% in the comparison group. These observations led to the present randomized study of the use of ice chips to prevent mucositis in patients receiving high-dose melphalan.
Materials and methods

Patients
From August 2003 to June 2005, 41 patients with multiple myeloma scheduled to receive melphalan 200 mg/m 2 were randomized to receive either ice chips or room temperature normal saline rinses before, during and after an infusion of melphalan, 2 days before peripheral blood stem cell transplantation (PBSCT). Patients were provided with informed consent for the study using a protocol and consent forms approved by the FHCRC institutional review board. All patients were offered the protocol but some refused it owing to oral sensitivity to cold.
This study examined the administration of ice chips to the oral cavity before, during and after the intravenous administration of melphalan compared with room temperature normal saline rinses to observe if severe mucositis could be reduced. The primary objective was to determine whether the use of ice chips before and following melphalan could reduce grade 3-4 mucositis compared to the use of room temperature normal saline mouth rinses. Secondary objectives were to determine whether the number of days of intravenous narcotic therapy for oral mucositis pain and the use of TPN after autologous transplantation could be reduced.
Eligibility included patients aged 18 or older with multiple myeloma who were scheduled to undergo a regimen of single-agent melphalan 200 mg/m 2 followed by PBSCT. Only patients who had not had a prior autologous transplant were eligible. Patients were stratified by age less than or greater than 60 years because of prior studies demonstrating that older patients were more susceptible to mucositis. 13 After obtaining signed informed consent and registration, patients were randomized to receive either ice chips or room temperature normal saline rinses. The normal saline was chosen as a comparison to control for any possible effect that rinsing of the mouth could have on the subsequent development of mucositis. Patients were informed of the randomization results and instructed how to document their use of ice chips or saline on a chart designed for that purpose.
Forty-one patients were randomized, with 21 receiving ice chips and 20 receiving normal saline. One patient who was randomized to normal saline withdrew consent for the study because he wanted to use ice chips. Data are not available for this patient, so results are reported for 21 patients who received ice chips and 19 who received normal saline.
Treatment
Melphalan was administered 2 days before (day À2) stem cell infusion (day 0). On day À2, patients began placing ice chips in their mouths or rinsing their mouths with room temperature normal saline 30 min before the melphalan infusion started. In patients randomized to ice chips, they were instructed to place approximately 1 ounce of crushed ice in the mouth. The ice was allowed to melt and replenished as soon as it had completely melted. Patients were instructed to continue this procedure for 6 h after the end of the 30-min melphalan infusion. Patients randomized to saline rinses were instructed to swish 1 ounce of room temperature normal saline in the mouth and spit it out every 30 min. Patients were instructed not to eat or drink anything extremely hot or extremely cold during this time period. On day 1, there was a day of rest. On day 0, cryopreserved peripheral blood stem cells were thawed and infused immediately thereafter.
Patients were requested to fill out a one-page questionnaire every day from day 2 until day 28. Questions addressed the patient's overall health, mouth and throat soreness, and recorded any difficulties with swallowing, drinking, eating, talking, sleeping and gustation. Patients were asked to rate mouth and throat soreness on a scale from 0 to 10, with 0 being no soreness and 10 being the worst they have ever experienced. Patients were asked to rate the degree of difficulty with each activity as no difficulty, a little, some, a lot and unable to perform at all. The answers were given a point value from 0 (no difficulty) to 4 (unable to perform at all). These data were collected daily for each patient.
Oral assessments were done by the clinical providers and nurses as part of their routine care. Data were collected from in-patient and outpatient medical records as well as the patient diaries. Mucositis was assessed according to the National Cancer Institute (NCI) Common Toxicity Criteria in Table 1 .
Statistics
The sample size of 40 was chosen to provide 91% power to observe a statistically significant difference (at the twosided significance level of 0.05) in the probability of grades 3-4 mucositis under the assumption that the true probabilities of severe mucositis are 0.25 for patients receiving ice chips and 0.75 for patients receiving normal saline. The maximum grade of mucositis from day À2 to day 28 was used for purposes of comparing probabilities of grades 3-4 mucositis. This comparison was made with the w 2 test. Days of TPN use, i.v. narcotics use and hospitalization were compared using the two-sample t-test. The maximum value of each patient-reported event was gathered and the average of these maximum values were compared between groups using the two-sample t-test. In addition to these analyses, generalized estimating equations (GEEs) were used, allowing the data points for each day to be utilized. A Table 1 NCI common toxicity criteria
Grade for mucositis was used to grade mucositis Grade 0 -no mucositis Grade 1 -painless ulcers, erythema or mild soreness without lesions Grade 2 -painful erythema, edema or ulcers but can swallow Grade 3 -painful erythema, edema or ulcers preventing swallowing or requiring hydration or TPN Grade 4 -severe ulceration requiring prophylactic intubation Abbreviations: NCI ¼ National Cancer Institute; TPN ¼ total parenteral nutrition.
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Results
Patient characteristics, transplant and engraftment results are shown in Table 2 . All patients received melphalan 200 mg/m 2 as prescribed. Although the prescribed duration of time for patients to use ice chips was for 6 h, compliance was not universal. Fourteen patients documented ice chip use for at least 5 h after melphalan and two patients for more than 2 h. Five patients did not report specific times of ice-chip usage. Some patients complained of the coldness of the ice chips so they stopped using the ice chips. The average amount of ice chips used was about 1 cup per hour. Normal saline rinses were 1-4 rinses per hour.
National Cancer Institute mucositis scores
The maximum NCI grades for mucositis from day 2 to 28 are summarized in Table 3 . National Cancer Institute grade 3 mucositis occurred at some point among three patients (14%) in the group receiving ice chips and among 14 patients (74%) in the group using normal saline rinses (P ¼ 0.0005). No patient in either group developed grade 4 mucositis. The average number of days in which grade 3 mucositis occurred was 0.5 days in the ice-chip group and 4.6 days in the normal-saline group (P ¼ 0.0001). Using an average daily mucositis scores for each patient, the mean of these average grades in the group receiving normal saline was 1.06 compared to a mean of 0.41 in the ice-chip group (P ¼ 0.0005). The same qualitative conclusions were reached using GEE (data not shown). Daily median NCI mucositis scores were calculated for each treatment group and are presented graphically in Figure 1 .
Patient reports
Four patients, two in each group, did not fill out any questionnaires reporting pain or other activities (Table 4) . The average number of days in which patients reported a score for mouth pain was similar between the two groups (17.7 days for ice chips, 16.9 days for normal saline) (P ¼ 0.83). The overall mean of the average mouth pain scores was 2.7 for the group that did not receive ice chips and 0.6 for the ice-chip group (P ¼ 0.003). Daily patient self-reported pain scores were calculated for each group and are displayed graphically in Figure 2 . Table 2 Daily patient-reported mouth pain scores, median of each group Mean of the highest value for each patient.
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Discussion
In this study, 40 patients receiving high-dose melphalan followed by PBSCT utilized cryotherapy or normal saline rinses before, during and after chemotherapy. Compared to the normal saline group, the patients who used cryotherapy had lower average NCI mucositis scores, a lower incidence of grades 3-4 mucositis, less use of narcotics and TPN, and lower average patient-reported pain scores. Each of these differences was statistically significant. In addition, patientreported activities of swallowing, eating, drinking, talking, sleeping and taste were less impaired in the cryotherapy group, and each of these differences was statistically significantly or suggestively different. These data support the hypothesis that cryotherapy reduces the severity and incidence of mucositis, with resulting clinical benefit in patients undergoing high-dose melphalan. The presumed mechanism of action of the protective effects of cryotherapy is vasoconstriction with resultant reduction in drug delivery to the oral mucosa. It is also possible, however, that cryotherapy may reduce the metabolic function of epithelial and basal cells in the mucosa, making them less susceptible to chemotherapy damage. We prescribed cryotherapy for 30 min before melphalan and for 6 h following the infusion of melphalan. It is entirely possible that a much shorter period of cryotherapy, that is 2-4 h of ice chip treatments, would work as well as the terminal elimination phase of intravenous melphalan is 75 min, but this would need to be studied. 14 There are other available treatments for the prevention of mucositis in patients undergoing high-dose chemotherapy or radiotherapy before PBSCT. In at least two prospective randomized trials, low-level helium-argon laser therapy was shown to reduce ulcerative mucositis in patients undergoing PBSCT. Lasers appear to have an analgesic effect and may promote wound healing, but the precise cellular mechanisms of action are not clear. 7, 15 Amifostine, a thiol-based cytoprotective agent, has been shown to reduce mucositis associated with high-dose melphalan. 8 Amifostine-treated patients had a reduction in the overall incidence of mucositis and less frequent severe mucositis. There was not, however, any difference in the utilization of parenteral nutrition or narcotics for pain relief. In a recent double-blind randomized study in pediatric patients undergoing PBSCT, oral glutamine supplements were associated with a trend to less mucositis and statistically lower use of TPN and narcotics for pain relief. 16 Palifermin (recombinant human keratinocyte growth factor), a cytokine belonging to the epidermal growth factor family, has recently been approved by the FDA to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies who are receiving high-dose therapy with HSCT support. 17 It appears that, in order to be effective, patients must receive palifermin for 3 days before the start of high-dose conditioning and 3 days post transplant.
Cryotherapy can be applied without the need for prior treatment. Furthermore, it is extremely well tolerated and cost effective. This treatment could be utilized with other cytoprotective protocols to further reduce the effects of mucositis. It is unknown, however, whether cryotherapy can be tolerated or would be effective with regimens requiring multiple days of treatment, with other drugs that may have a prolonged elimination phase or multiple days of radiotherapy. Cryotherapy to prevent mucositis after high-dose melphalan K Lilleby et al
